Lapatinib is a small-molecule tyrosine kinase inhibitor that targets EGFR and HER2, with unclear effects on pyruvate kinase type M2 (PKM2), and is used in the treatment of advanced HER-2-positive breast cancers [53,54]. This evidence concerns the gene EGFR and breast carcinoma.